EFONIDIPINE HCL manufacturers
- EFONIDIPINE HCL
-
- $1.00 / 1KG
-
2019-12-26
- CAS:111011-53-1
- Min. Order: 1KG
- Purity: ≥98%
- Supply Ability: g/kg/Ton
|
| | EFONIDIPINE HCL Basic information |
| Product Name: | EFONIDIPINE HCL | | Synonyms: | EFONIDIPINE HCL;Efonidipine hydrochloride;EFONIDIPINE HCL ETHANOL;3-Pyridinecarboxylicacid,5-(5,5-diMethyl-2-oxido-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-diMethyl-4-(3-nitrophenyl)-,2-[phenyl(phenylMethyl)aMino]ethyl ester, hydrochloride (1:1);2-(N-benzylanilino)ethyl5-(5,5-dimethyl-2-oxo-1,3,2λsup5sup-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate,hydrochloride | | CAS: | 111011-53-1 | | MF: | C34H38N3O7P.ClH | | MW: | 668.123 | | EINECS: | | | Product Categories: | | | Mol File: | 111011-53-1.mol |  |
| | EFONIDIPINE HCL Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 8.5 mg/mL (12.72 mM) |
| Toxicity | LD50 in mice (mg/kg): >600 orally (Seto) |
| | EFONIDIPINE HCL Usage And Synthesis |
| Uses | Efonidipine Hcl (NZ-105) is a dual T-type and L-type calcium channel blocker (CCB).
IC50 value:
Target: calcium channel blocker
in vitro: Efonidipine and nifedipine, but not other examined CCBs, also increased the N(6), 2'-O-dibutyryladenosine 3',5'-cyclic monophosphate (dbcAMP)-induced StAR mRNA, which reflects the action of adrenocorticotropic hormone, and efonidipine and R(-)-efonidipine enhanced the dbcAMP-induced DHEA-S production in NCI-H295R adrenocortical carcinoma cells [1]. I(Ca(T)) was blocked mainly by a tonic manner by nifedipine, by a use-dependent manner by mibefradil, and by a combination of both manners by efonidipine. IC50s of these Ca2+ channel antagonists to I(Ca(T)) and L-type Ca2+ channel current (I(Ca(L))) were 1.2 micromol/l and 0.14 nmol/l for nifedipine; 0.87 and 1.4 micromol/l for mibefradil, and 0.35 micromol/l and 1.8 nmol/l for efonidipine, respectively [4].
in vivo: Twenty hypertensive patients on chronic hemodialysis were given efonidipine 20-60 mg twice daily and amlodipine 2.5-7.5 mg once daily for 12 weeks each in a random crossover manner. The average blood pressure was comparable between the efonidipine and amlodipine periods (151 + or - 15/77 + or - 8 versus 153 + or - 15/76 + or - 8 mmHg). The pulse rate did not change significantly during the administration periods [2]. In the UM-X7.1 group, EFO treatment significantly attenuated the decrease of LVEF without affecting blood pressure compared with the vehicle group. EFO treatment decreased heart rate (by approximately 10%) in both groups [3]. | | References | [1] Ikeda K, et al. Efonidipine, a Ca(2+)-channel blocker, enhances the production of dehydroepiandrosterone sulfate in NCI-H295R human adrenocortical carcinoma cells. Tohoku J Exp Med. 2011;224(4):263-71. DOI:10.1620/tjem.224.263
[2] Nakano N, et al. Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin-angiotensin-aldosterone system in chronic hemodialysis patients. Int Heart J. 2010 May;51(3):188-92. DOI:10.1536/ihj.51.188
[3] Suzuki S, et al. Beneficial effects of the dual L- and T-type Ca2+ channel blocker efonidipine on cardiomyopathic hamsters. Circ J. 2007 Dec;71(12):1970-6. DOI:10.1253/circj.71.1970
[4] Lee TS, et al. Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20. DOI:10.1159/000094900 |
| | EFONIDIPINE HCL Preparation Products And Raw materials |
|